目的 探讨瑞舒伐他汀对急性冠脉综合征(ACS)患者血脂与CRP的影响及疗效。方法 纳入2012年1月至2015年1月 来我院就诊的ACS患者90例，随机分为观察组和对照组，每组45例，给予观察组瑞舒伐他汀治疗，给予对照组 阿托伐他汀治疗，均治疗28d。治疗前后检测并比较两组患者血脂包括TG、TC、HDL、LDL和hs-CRP水平，并观察 两组治疗后临床疗效及不良反应发生情况。结果 两组治疗后较治疗前TG、TC、LDL及hs-CRP水平均显著降低(P ＜0.05)；与对照组比较，治疗后观察组TG、LDL、hs-CRP水平分别为(1.40±0.17)mmol/L、(2.60±0.49)mmol/L、 (6.46±2.01)mg/L显著较低(P＜0.05)；治疗后观察组LDL达标率为82.22%、hs-CRP达标率为88.89%均显著高于对照 组(P＜0.05)；观察组治疗总有效率为91.11%显著高于对照组75.56%，且不良反应发生率为6.67%显著低于对照组 24.44%(P＜0.05)。结论 与阿托伐他汀治疗相比，瑞舒伐他汀对ACS患者血脂及CRP的改善效果更明显，疗效更显著 且可极大降低不良反应发生率，安全性更高。

Objective To analyze the clinical effect of rosuvastatin on blood lipid and CRP in patients with acute coronary syndrome (ACS). Methods From Jan. 2012 to Jan. 2015, a total of 90 patients with ACS were selected in our hospital and randomly divided into observation group (45 cases) and control group (45 cases). Patients in the control group were given atorvastatin, the other patients in the observation group were given rosuvastatin, and both of them were treated for 28 days. After treatment, the blood lipid levels including TG, TC, HDL, LDL and hs-CRP were compared, clinical effects and adverse reactions were recorded. Results Both the two group of TG, TC, HDL, LDL and hs-CRP were significantly lower than that before treatment (P<0.05). After treatment, the TG, LDL and hs-CRP levels of the observation group were (1.40±0.17)mmol/L,(2.60±0.49)mmol/L and (6.46±2.01)mg/L which were significantly lower than those of the control group (P<0.05), and the success rates of LDL and hs-CRP were 82.22% and 88.89% which were significantly higher than those of the control group (P<0.05), the total effective rate of the observation group was 91.11% which was significantly higher than that of the control group 75.56%, the adverse reactions rate of the observation group was 6.67% which was significantly lower than that of the control group 24.44%(P<0.05). Conclusion Compared with atorvastatin, rosuvastatin can effectively improve blood lipid and CRP in patients with ACS and greatly reduce the incidence of adverse reactions.